Unknown

Dataset Information

0

Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2.

ABSTRACT: SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection.

SUBMITTER: Scott TA 

PROVIDER: S-EPMC8806709 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2.

Scott Tristan A TA   Supramaniam Aroon A   Idris Adi A   Cardoso Angelo A AA   Shrivastava Surya S   Kelly Gabrielle G   Grepo Nicole A NA   Soemardy Citradewi C   Ray Roslyn M RM   McMillan Nigel A J NAJ   Morris Kevin V KV  

Molecular therapy. Methods & clinical development 20220202

SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to n  ...[more]

Similar Datasets

Unknown Quantitative proteomics and biological activity of extracellular vesicles engineered to express SARS-CoV-2 spike protein.
| S-EPMC9874654 | biostudies-literature
Unknown Tilt series of SARS-CoV-2 spike-bearing virus-like particles (VLPs) interacting with hACE2-bearing extracellular vesicles (tEVs), showing various intermediate states of the SARS-CoV-2 spike protein
| EMPIAR-10788 | biostudies-other
Unknown Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.
| S-EPMC7769856 | biostudies-literature
Unknown Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.
| S-EPMC8213968 | biostudies-literature
Unknown Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.
| S-EPMC8427979 | biostudies-literature
Unknown Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.
| S-EPMC10458444 | biostudies-literature
Unknown Epitope-directed anti-SARS-CoV-2 scFv engineered against the key spike protein region could block membrane fusion.
| S-EPMC9926471 | biostudies-literature
Unknown Salivary extracellular vesicles inhibit Zika virus but not SARS-CoV-2 infection.
| S-EPMC7480612 | biostudies-literature
Unknown Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling.
| S-EPMC8841010 | biostudies-literature
Unknown Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein.
| S-EPMC9318727 | biostudies-literature